Tricor, Fenofibrate News

Main Category: Cholesterol Also Included In: Clinical Trials / Drug Trials Article Date: 18 Jun 2009 - 0:00 PDT printer friendly view / write opinions rate article Aegerion Pharmaceuticals, Inc., a biopharmaceutical company focused on the treatment of cardiovascular and metabolic disease, announced final data from three separate Phase II trials ...

Fenofibrate therapy lowers the incidence of cardiovascular disease in women more so than in men, according to results of the Fenofibrate and Event Lowering in Diabetes study.

Solvay SA , the Belgian chemicals, plastics and drugs company, is set to receive a range of proposals for its pharmaceutical unit by Friday's deadline for indicative bids, people familiar with the matter said.

Abstract Exposure to polychlorinated biphenyls can activate inflammatory responses in vascular endothelial cells.

What's the latest news in the medical journals this month? Find out what your doctor is reading.

Doctors who gave diabetics a drug originally intended to lower patients' cholesterol found it reduced their risk of so-called minor amputation by 36 percent, a new analysis of research says.

People with diabetes who were prescribed the cholesterol-lowering drug fenofibrate reduced their risk of minor amputations by 36 per cent, according to new research.

HONG KONG: The anti-cholesterol drug fenofibrate appears to reduce risks of amputation for diabetics by as much as 36 percent, a study has found.

May 21, 2009 -- Treating type 2 diabetes patients with a cholesterol -lowering drug called fenofibrate cuts the risk of a first diabetes -related limb amputation by 36%, according to a new study published this week in The Lancet.

Oscient Pharmaceuticals Corporation has received notification from the Listings Qualifications Department of The NASDAQ Stock Market LLC that since the Company has not filed its Form 10-Q for the period ended March 31, 2009, the Company is no longer in compliance with Marketplace Rule 5250 .

THE anti-cholesterol drug fenofibrate appears to reduce risks of amputation for diabetics by as much as 36 per cent, a study has found.

Doctors who gave diabetics a drug originally intended to lower patients' cholesterol found it reduced their risk of so-called minor amputation by 36 percent, a new analysis of research says.

The study encompassed both patients with very high triglycerides and mixed dyslipidemia and included normal weight, overweight and obese patients presenting with or without hypertension.

Adiponectin is inversely associated with obesity, insulin resistance, and atherosclerosis, but little is known about the genetic pathways that regulate the plasma level of this protein.

From Cardiothoracic Pharmacology , National Heart and Lung Institute, Imperial College, London, UK; The William Harvey Research Institute , Barts and the London School of Medicine and Dentistry, Queen Mary University of London, UK; and The Ernest Cooke Vascular & Microvascular Unit , St.

Drug and medical-device company Abbott Laboratories reports first-quarter earnings for 2009 on Wednesday morning.

All the peroxisome proliferator activated receptors are found to be expressed in bone cells.

From the Department of Medicine , Helsinki University Central Hospital, Biomedicum, Helsinki, Finland; the Department of Clinical Biochemistry , Royal Prince Alfred Hospital, Camperdown, NSW Australia; the Department of Molecular Medicine , National Public Health Institute, Biomedicum, Helsinki, Finland; the Department of Medical Chemistry , ...

Oscient Pharmaceuticals Corporation will release financial results for the fourth quarter and fiscal year ended December 31, 2008 on Thursday, March 26, 2009, prior to the opening of the U.S. financial markets.

Diabetic cardiomyopathy contributes to cardiac failure in diabetic patients. It is characterized by excessive lipids accumulation, with increased triacylglycerol stores, and fibrosis in left ventricle .